A Remarkable Result of a Double-Masked, Placebo-Controlled Trial of Erythromycin in the Treatment of Pityriasis Rosea

Bigby, Michael

doi:10.1001/archderm.136.6.775

Cited by 14 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of our patients in both groups achieved complete response during the first two weeks of treatment. This is contrary to some other trials[111516] that reported complete response after two weeks of treatment in their subjects. After eight weeks, the rate of complete response in patients who received high-dose acyclovir was significantly higher than their matches who received oral erythromycin.…”

Section: Discussioncontrasting

confidence: 99%

The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea

et al. 2010

View full text Add to dashboard Cite

Background:Pityriasis Rosea (PR) is an acute inflammatory and self-limiting skin disorder, sometimes with troublesome symptoms. To date, there are few treatments available for this disorder.Aim:Compare the traditional treatment with erythromycin to a newly introduced antiviral treatment acyclovir for PR.Materials and Methods:Patients with clinically confirmed diagnosis of PR, matching our exclusion criteria, were enrolled. They were randomized in two groups that received high-dose oral acyclovir or erythromycin. The participants were evaluated two, four, and eight weeks after commencement of the study and followed for one year.Results:A total of 30 patients including 15 males and 15 females completed the study. After eight weeks, 13 patients in the acyclovir group experienced complete response, while in the erythromycin group only six patients had complete response (P < 0.05). Also, patients in the acyclovir group experienced faster resolution of pruritus in comparison with the erythromycin group (not significant). No adverse drug reaction was detected in both groups.Conclusion:It seemed that a high-dose of oral acyclovir was a safe and effective therapy for PR, although this remained to be confirmed in larger studies.

show abstract

Section: Discussioncontrasting

confidence: 99%

The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea

et al. 2010

View full text Add to dashboard Cite

show abstract

“…One double‐blind, placebo‐controlled study 7 reported the benefit of erythromycin in modifying the course of PR. Criticisms on this study 12,21 are beyond the scope of the present discussion. It is worth pointing out, however, that the presence and the severity of pruritus were not documented.…”

Section: Discussionmentioning

confidence: 90%

Effect on quality of life in patients with pityriasis rosea: Is it associated with rash severity?

Chuh

Chan

2005

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“… 32 Nevertheless, this study had methodological deficiencies in randomization, allocation concealment and analysis, with the adverse events inherent to macrolides. 33 Other studies suggested immunomodulatory and anti-inflammatory effects of macrolides in PR due to Chlamydia, Legionella and Mycoplasma involvement, but not assertively. 34 - 36 Clinical trials have shown that efficacy of macrolides, such as erythromycin, clarithromycin and azithromycin has not been proven.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis

Rodríguez-Zúñiga

Torres

García‐Perdomo

2018

An. Bras. Dermatol.

View full text Add to dashboard Cite

BackgroundThere is a lack of evidence to support acyclovir administration in pityriasis rosea.ObjectiveTo determine the efficacy of acyclovir in patients with typical pityriasis rosea.MethodsA systematic review and meta-analysis of experimental studies was performed in MEDLINE, SCOPUS, EMBASE and others, from January 1990 to October 2016 on acyclovir for pityriasis rosea. Random effect model was used to find the pooled Risk Ratio. Outcomes, evaluated between weeks 1 to 8, were regression of lesions, cessation of lesions, decrease of symptoms and duration of disease. Comparisons were acyclovir vs. placebo; acyclovir vs. symptomatic treatment; acyclovir vs. antibiotic; acyclovir vs. observation and combined therapy (acyclovir plus symptomatic treatment) vs. symptomatic treatment alone.ResultsSeven papers were analyzed with 324 participants, of which 159 received acyclovir and 165 were controls. Acyclovir was superior to placebo for complete regression of lesions at week 1 (Risk Ratio 5.72, CI95% 2.36-13.88). However, combined therapy was not superior to symptomatic treatment at week 4 (Risk Ratio 1.46, CI95% 0.93-2.29). Individual studies showed the superiority of acyclovir for the control of symptoms and pruritus.Study limitationsWe faced differences designs of trials and inconsistency between reports.ConclusionSymptomatic treatment is a reasonable option for pityriasis rosea, and the addition of acyclovir is justified for the control of symptoms and pruritus.

show abstract

A Remarkable Result of a Double-Masked, Placebo-Controlled Trial of Erythromycin in the Treatment of Pityriasis Rosea

Cited by 14 publications

References 0 publications

The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea

The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea

Effect on quality of life in patients with pityriasis rosea: Is it associated with rash severity?

Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis

Contact Info

Product

Resources

About